(Q46886196)

26 December 2017

review article

1 reference

title

Tobacco and schizophrenia: therapeutic aspects (English)

1 reference

26 December 2017

1 reference

A Dervaux

1

1 reference

26 December 2017

X Laqueille

series ordinal

2

1 reference

26 December 2017

publication date

1 September 2007

1 reference

26 December 2017

L'Encephale: revue de psychiatrie clinique biologique et therapeutique

number of pages

4

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 December 2017

volume

33

1 reference

26 December 2017

issue

4 Pt 1

1 reference

26 December 2017

page(s)

629-632

1 reference

26 December 2017

Schizophrenia, sensory gating, and nicotinic receptors.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Nicotine dependence and symptoms in schizophrenia: naturalistic study of complex interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

The pathophysiology of cigarette smoking and cardiovascular disease: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Smoking impact on CYP1A2 activity in a group of patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Atypical antipsychotic dosing: the effect of smoking and caffeine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Schizophrenia and smoking: an epidemiological survey in a state hospital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A review of the pharmacological and psychopharmacological aspects of smoking and smoking cessation in psychiatric patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Nicotine use in schizophrenia: the self medication hypotheses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Smoking and therapeutic response to clozapine in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Clozapine decreases smoking in patients with chronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Haloperidol increases smoking in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Smoking and movement disorders in psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Individual changes in clozapine levels after smoking cessation: results and a predictive model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Cigarette smoking is associated with abnormal involuntary movements in the general male population--a study of men born in 1933.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Prevalence of smoking in psychiatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Treatment of tobacco use in an inpatient psychiatric setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Smoking and cognitive deficits in schizophrenia: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Serious mental illness and tobacco addiction: a model program to address this common but neglected issue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0013-7006%2807%2992064-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0013-7006(07)92064-3

1 reference

26 December 2017

PubMed ID

18033154

1 reference

26 December 2017